Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

15.90 +0.06 (+0.38%)

Streaming Delayed Price Updated: 10:38 AM EDT, Sep 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 19, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

August 19, 2026

Via Chartmill

Arcturus (ARCT) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Regaining vaccine rights and advancing rare disease programs toward key 2026 milestones.

Via The Motley Fool

Topics Earnings

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances ↗

May 07, 2026

Via Chartmill

Arcturus Therapeutics (NASDAQ:ARCT) Stock Falls After Q4 2025 Revenue Miss ↗

March 03, 2026

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Preview: Arcturus Therapeutics's Earnings ↗

November 07, 2025

Via Benzinga

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline ↗

August 11, 2026

Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is...

Via MarketBeat

Arcturus Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Arcturus Therapeutics (NASDAQ:ARCT) reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase...

Via MarketBeat

Topics Earnings

Thursday's session: gap up and gap down stocks ↗

July 02, 2026

Via Chartmill

Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies ↗

June 05, 2026

Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the...

Via MarketBeat

Arcturus (ARCT) Q1 2026 Earnings Call Transcript ↗

May 08, 2026

Arcturus (ARCT) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

May 07, 2026

Via Chartmill

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

March 25, 2026

The widely followed investor has been buying stocks trading well below their all-time highs.

Via The Motley Fool

These Are the Only 3 Stocks That Cathie Wood Bought Last Week ↗

March 23, 2026

The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting.

Via The Motley Fool

Topics Artificial Intelligence ETFs

Arcturus (ARCT) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

Arcturus (ARCT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Lawsuit

Arcturus Therapeutics (NASDAQ:ARCT) Reports Mixed Q3 2025 Results, Extends Cash Runway to 2028 ↗

November 10, 2025

Arcturus Q3 2025 results show a revenue miss but a smaller-than-expected loss. The company advances its CF and OTC programs, with cash extending into 2028.

Via Chartmill

This Molina Healthcare Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday ↗

October 24, 2025

Via Benzinga

Cathie Wood Goes Shopping: 3 Stocks She Just Bought ↗

October 23, 2025

The growth-focused money manager only bought three stocks on Wednesday. Let's check out that shopping list.

Via The Motley Fool

Topics ETFs

Where Arcturus Therapeutics Stands With Analysts ↗

October 22, 2025

Via Benzinga

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture ↗

October 22, 2025

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

October 22, 2025

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Crude Oil Gains Over 1%; AT&T Shares Slide After Q3 Results ↗

October 22, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 22, 2025

Via Benzinga

Top movers in Wednesday's session ↗

October 22, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

October 22, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Dow Falls 100 Points; Netflix Shares Tumble On Downbeat Earnings ↗

October 22, 2025

Via Benzinga

Topics Stocks

Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off? ↗

October 22, 2025

The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.

Via Stocktwits

Arcturus Crashes 55% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug ↗

October 22, 2025

The company is working on a treatment for cystic fibrosis using messenger RNA, or mRNA, technology.

Via Investor's Business Daily

Wednesday's pre-market session: top gainers and losers ↗

October 22, 2025

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.